Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
Ilaria Dicembrini, Besmir Nreu, Chiara Montereggi, Edoardo Mannucci, Matteo Monami
Topics & Concepts
AlogliptinSitagliptinMedicineVildagliptinSaxagliptinInternal medicineLinagliptinPlaceboOdds ratioRandomized controlled trialMeta-analysisDipeptidyl peptidase-4Dipeptidyl peptidase-4 inhibitorRelative riskType 2 diabetesConfidence intervalDiabetes mellitusOncologyMetforminEndocrinologyPathologyInsulinAlternative medicineDiabetes Treatment and ManagementPeptidase Inhibition and AnalysisNeuroendocrine Tumor Research Advances